MedTrace Logo

Donor Derived Cell-free DNA and Rejection of Kidney Allografts

NCT05995379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2023-08-16

No results posted yet for this study

Summary

To assess the association of dd-cfDNA with the presence, activity and severity of allograft rejection, and determine whether dd-cfDNA adds value to standard of care monitoring parameters in detecting kidney allograft rejection.

Conditions

  • Kidney Rejection Transplant

Interventions

DIAGNOSTIC_TEST

Donor-derived cell-free DNA

Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection. One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed.

Sponsors & Collaborators

  • Paris Translational Research Center for Organ Transplantation

    lead OTHER

Principal Investigators

  • Alexandre Loupy · Paris Institute for Transplantation and Organ Regeneration

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-21
Primary Completion
2022-08-09
Completion
2022-08-09

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05995379 on ClinicalTrials.gov